Sign Up Today and Learn More About Mammoth Biosciences Stock
Invest in or calculate the value of your shares in Mammoth Biosciences or other pre-IPO companies through EquityZen's platform.
Mammoth Biosciences Stock (MABI)
Mammoth Biosciences leverages its proprietary ultra-compact CRISPR platform for gene editing therapies, disease detection, and research.
Mammoth Biosciences develops novel CRISPR applications for disease detection, research, agriculture, biodefense, and more.
About Mammoth Biosciences Stock
Founded
2017
Headquarters
San Francisco, CA, US
Total Funding
379M
Industries
Science and Engineering, Health Care, Biotechnology
Mammoth Biosciences is a developer of a ultracompact CRISPR system for diagnostics, protein discovery, and genome therapeutics. The company identifies Cas enzymes and associated technologies to perform edits in-vivo to offer potentially curative treatments for patients with unmet needs.
Mammoth Biosciences Press Mentions
Stay in the know about the latest news on Mammoth Biosciences
Mammoth Biosciences to Present at 44th Annual J.P. Morgan Healthcare Conference
biospace • Jan 11, 2026
Occam Global Strengthens Life Science Leadership with Transformative 2025
prweb • Dec 11, 2025
Scientists say finding extraterrestrial life and curing all genetic diseases could both happen in the next decade
betanews • Nov 23, 2025
The Risk of Funding Cuts to Scientific Discovery
marketscreener • Nov 22, 2025
“All Genetic Diseases Could be Cured within a Decade”, Hears Dubai Future Forum
businesswire • Nov 20, 2025
Investors in Mammoth Biosciences
Discover investors in Mammoth Biosciences stock and explore their portfolio companies
Mammoth Biosciences Management
Leadership team at Mammoth Biosciences
Co-Founder & Chief Executive Officer
Trevor Martin
Chief Financial Officer & Chief Operating Officer
Elaine Sun
Join now and verify your accreditation status to gain access to:
- Mammoth Biosciences Current Valuation
- Mammoth Biosciences Stock Price
- Mammoth Biosciences Management
- Available deals in Mammoth Biosciences and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Mammoth Biosciences Cap Table and Funding History by Share Class and Liquidity Preferences
- Mammoth Biosciences Revenue and Financials
- Mammoth Biosciences Highlights
- Mammoth Biosciences Business Model
- Mammoth Biosciences Risk Factors
- Mammoth Biosciences Research Report from SACRA Research
Mammoth Biosciences Key Facts
- Expansion of CRISPR diagnostics footprint via VedaBio licensing: In September 2025, VedaBio announced a non‑exclusive licensing agreement to use selected Mammoth CRISPR technologies in its rapid molecular‑detection platform, giving VedaBio access to “foundational” CRISPR IP for decentralized diagnostic applications. This deal, reiterated in a January 11, 2026 update, extends Mammoth’s reach into point‑of‑care and near‑patient testing through a partner that is investing to commercialize amplification‑free assays, helping to monetize Mammoth’s IP portfolio while diversifying downstream product bets beyond its own internal diagnostic programs.Â
- Advancing in vivo gene‑editing pipeline, including MB‑111: Mammoth has highlighted progress on its wholly owned in vivo gene‑editing therapeutics, including preclinical data for candidate MB‑111 to be presented at the European Society of Gene & Cell Therapy 32nd Annutal Congress in October 2025. Company communications emphasize the use of proprietary ultra‑compact CRISPR systems (such as Casɸ) designed for delivery into challenging tissues, supporting a differentiated positioning versus larger CRISPR nucleases and strengthening Mammoth’s narrative as a platform capable of long‑term, potentially curative therapies.
- Operational Restructuring and Human Capital Risk: In May 2025, Mammoth Biosciences executed a workforce reduction of 24 employees, representing approximately 13% of its staff at the time. This move was part of a broader biopharma trend of "triage," as companies narrowed their focus to lead candidates to preserve cash in a challenging capital market. While intended to streamline the path for its lead drug candidate, MB-111, such layoffs can lead to "brain drain" and internal disruption, especially as well-funded rivals like Scribe Therapeutics and Metagenomi compete for the same specialized talent in metagenomics and protein engineering.
- Regulatory Uncertainty and Clinical Execution Risks: As Mammoth prepares to move MB-111 into the clinic in 2026, it enters a highly scrutinized regulatory environment. The EU AI Act and new FDA guidance on genomic data provenance (effective early 2026) mandate unprecedented transparency in how AI-discovered enzymes are designed and tested. Any preclinical setbacks or delays in obtaining Investigational New Drug (IND) clearance could significantly impact the company’s valuation and delay its projected 2027 IPO window, particularly as investors shift their focus from "platform potential" to "clinical proof-of-concept."
Trading Mammoth Biosciences Stock
How to invest in Mammoth Biosciences stock?
Accredited investors can buy pre-IPO stock in companies like Mammoth Biosciences through EquityZen funds. These investments are made available by existing Mammoth Biosciences shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Mammoth Biosciences stock?
Shareholders can sell their Mammoth Biosciences stock through EquityZen's private company marketplace. EquityZen's network includes over 420K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 51K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
